The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.

@article{Oliver2021TheAC,
  title={The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.},
  author={Sara E Oliver and Julia W Gargano and Mona Marin and Megan Wallace and Kathryn G. Curran and Mary E. Chamberland and Nancy McClung and Doug E Campos-Outcalt and Rebecca L. Morgan and Sarah A Mbaeyi and Jos{\'e} R. Romero and H. Keipp B. Talbot and Grace M. Lee and Beth P. Bell and Kathleen L. Dooling},
  journal={MMWR. Morbidity and mortality weekly report},
  year={2021},
  volume={69 5152},
  pages={
          1653-1656
        }
}
On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). This vaccine is the second COVID-19 vaccine authorized under an EUA for the prevention of COVID-19 in the… 
The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
TLDR
It is found that the benefits of preventing symptomatic and asymptomatic SARS-CoV-2 infection, hospitalization, and death outweigh vaccine-associated risks of the Moderna COVID-19 vaccine.
First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021
TLDR
The initial postauthorization safety profiles of the two COVID-19 vaccines in current use did not indicate evidence of unexpected serious adverse events, and descriptive analyses of safety data from the first month of vaccination provided reassurance and helpful information regarding what health care providers and vaccine recipients might expect after vaccination.
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
TLDR
The benefits of CO VID-19 vaccination in preventing COVID-19 morbidity and mortality outweigh the risks for these rare serious adverse events in adults aged ≥18 years; this balance of benefits and risks varied by age and sex.
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021
  • anonymous
  • Medicine
    MMWR. Morbidity and mortality weekly report
  • 2021
TLDR
This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphyl Kaplan-like reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020-January 10, 2021, in the United States.
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID‐19 vaccine — United States, December 21, 2020–January 10, 2021
  • T. Shimabukuro
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2021
TLDR
This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphyl Kaplan-like reactions, after receipt of the first dose of Moderna COVID19 vaccine during December 21, 2020– January 10, 2021, in the United States.
Recommended Adult Immunization Schedule, United States, 2021
TLDR
The 2021 adult immunization schedule, published annually, is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist providers in implementing current ACIP recommendaitons.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021
TLDR
The Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2021 and an amendment to include COVID-19 vaccine recommendations in the child and adolescent and adult immunization schedules.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021
At its October 2020 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the 2021 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. After
COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials
TLDR
The concept and mechanisms of trained immunity induced by the Bacille Calmette Guérin (BCG) vaccine are reviewed and questions that should be answered are identified before the BCG vaccine could be used to combat COVID-19 pandemic.
...
1
2
3
4
5
...

References

The Advisory Committee on Immunization Practices’ Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
TLDR
The four ethical principles that will assist ACIP in formulating recommendations for the allocation of COVID-19 vaccine while supply is limited are described, in addition to scientific data and implementation feasibility, to maximize benefits and minimize harms.